ABECMA
Biological
Celgene Corporation
Total Payments
$28.3M
Transactions
1,936
Doctors
1,133
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $4.9M | 436 | 240 |
| 2023 | $7.7M | 243 | 154 |
| 2022 | $6.7M | 204 | 82 |
| 2021 | $9.0M | 1,053 | 724 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $27.7M | 261 | 97.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $282,671 | 103 | 1.0% |
| Consulting Fee | $165,596 | 78 | 0.6% |
| Food and Beverage | $62,399 | 1,320 | 0.2% |
| Travel and Lodging | $48,037 | 94 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $24,500 | 7 | 0.1% |
| Education | $2,435 | 73 | 0.0% |
Payments by Type
Research
$27.7M
261 transactions
General
$585,637
1,675 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide | Celgene Corporation | $4.7M | 0 |
| A Phase 3, Multicenter, Randomized, Open-label Stu | Celgene Corporation | $3.9M | 0 |
| Ph IIB Ide-Cel Multi-Cohort mono RRMM - A phase 2, multi-cohort, open-label, multicenter study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma and in subjects with clinical high-risk multiple myeloma | Celgene Corporation | $3.5M | 0 |
| PhIIb Ide-Cel Multi-cohort MM (1L, 2L, 4L+) KarMma-2 (bb2121-MM-002) - A phase 2, multi-cohort, open-label, multicenter study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma and in subjects with clin | Celgene Corporation | $3.1M | 0 |
| A phase 2, multi-cohort, open-label, multicenter s | Celgene Corporation | $2.9M | 0 |
| Ph IIB Ide-Cel Multi-Cohort mono RRMM (bb2121-MM-002; KarMMa-2) - A phase 2, multi-cohort, open-label, multicenter study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma and in subjects with clinical | Celgene Corporation | $1.9M | 0 |
| ABECMA in the real world - Moffitt Study 1 | Celgene Corporation | $1.1M | 0 |
| A Phase 1, Open-label, Multicenter Study to Evalua | Celgene Corporation | $1.0M | 1 |
| CRB-401A Phase 1 Study ofbb2121in BCMA-Expressing Multiple Myeloma | Celgene Corporation | $849,311 | 0 |
| A Phase 3, Multicenter, Randomized, Open-label Stu - A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) | Celgene Corporation | $836,664 | 0 |
| An Efficacy and Safety Study ofbb2121in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2) | Celgene Corporation | $698,848 | 0 |
| Bridging Study with Moffitt | Celgene Corporation | $503,290 | 0 |
| Efficacy and Safety Study ofbb2121in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) | Celgene Corporation | $499,297 | 0 |
| CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma | Celgene Corporation | $399,524 | 0 |
| PhIII Ide-Cel vs Triplet RRMM 3L - A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) | Celgene Corporation | $343,024 | 0 |
| A Phase 1, Open-label, Multicenter Study to Evalua - A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects with High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4) | Celgene Corporation | $288,686 | 0 |
| Feasibility assessment of wearable device for remote monitoring and immune correlates of patients with Multiple Myeloma Undergoing Chimeric Antigen Receptor T (CAR-T) Cell Therapy | Celgene Corporation | $259,309 | 0 |
| A Phase 2, Multicenter Study of the Safety and Eff | Celgene Corporation | $232,473 | 0 |
| PhII Ide-Cel in RRMM - A Phase 2, Multicenter Study of the Safety and Efficacy of bb2121 in Subjects with relapsed / refractory multiple myeloma | Celgene Corporation | $181,723 | 0 |
| A phase 2, multi-cohort, open-label, multicenter s - A phase 2, multi-cohort, open-label, multicenter study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma and in subjects with clinical high-risk mul | Celgene Corporation | $104,016 | 0 |
Top Doctors Receiving Payments for ABECMA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Phila, PA | $27.6M | 277 |
| , D.M.D | General Practice | Greenville, SC | $94,068 | 1 |
| , M.D | Hematology & Oncology | West Hollywood, CA | $35,386 | 31 |
| , MD | Internal Medicine | Indianapolis, IN | $22,969 | 13 |
| , M.D | Hematology & Oncology | Tampa, FL | $21,836 | 15 |
| , M.D | Hematology | Phoenix, AZ | $19,430 | 10 |
| , M.D | Hematology | Phoenix, AZ | $16,863 | 6 |
| , D.O | Hematology & Oncology | Miami, FL | $16,781 | 16 |
| , M.D | Hematology & Oncology | Tampa, FL | $15,617 | 9 |
| , M.D | Hematology & Oncology | San Antonio, TX | $12,611 | 10 |
| , M.D | Hematology | Hackensack, NJ | $12,211 | 7 |
| , MD | Medical Oncology | Boston, MA | $12,109 | 9 |
| , M.D | Internal Medicine | New York, NY | $12,060 | 5 |
| , M.D | Hematology & Oncology | Indianapolis, IN | $11,708 | 14 |
| , MD | Internal Medicine | Stony Brook, NY | $11,667 | 7 |
| , D.O | Hematology & Oncology | Greenville, SC | $11,361 | 8 |
| , M.D | Hematology & Oncology | Scottsdale, AZ | $10,974 | 8 |
| , M.D | Hematology & Oncology | Knoxville, TN | $10,364 | 5 |
| , MD | Internal Medicine | Seattle, WA | $10,078 | 12 |
| , MD | Hematology & Oncology | Cleveland, OH | $9,450 | 4 |
| , M.D | Specialist | Atlanta, GA | $8,878 | 6 |
| , M.D | Specialist | Sacramento, CA | $8,062 | 5 |
| , MD | Internal Medicine | Duarte, CA | $7,476 | 6 |
| , M.D | Hematology | Stanford, CA | $7,275 | 8 |
| , MD | Internal Medicine | Tampa, FL | $6,993 | 4 |
Ad
Manufacturing Companies
- Celgene Corporation $28.0M
- E.R. Squibb & Sons, L.L.C. $309,857
Product Information
- Type Biological
- Total Payments $28.3M
- Total Doctors 1,133
- Transactions 1,936
About ABECMA
ABECMA is a biological associated with $28.3M in payments to 1,133 healthcare providers, recorded across 1,936 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2021 to 2024. In 2024, $4.9M was paid across 436 transactions to 240 doctors.
The most common payment nature for ABECMA is "Unspecified" ($27.7M, 97.9% of total).
ABECMA is associated with 20 research studies, including "Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide" ($4.7M).